These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 36302567

  • 1. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA.
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH, Roth DA.
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [Abstract] [Full Text] [Related]

  • 3. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
    Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA.
    N Engl J Med; 2020 Sep 17; 383(12):1117-1128. PubMed ID: 32937045
    [Abstract] [Full Text] [Related]

  • 4. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.
    Lupus; 2018 Aug 17; 27(9):1489-1498. PubMed ID: 29807477
    [Abstract] [Full Text] [Related]

  • 5. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA.
    Kidney Int; 2022 Feb 17; 101(2):403-413. PubMed ID: 34560137
    [Abstract] [Full Text] [Related]

  • 6. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 17; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 7. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, Bozzolo E, Brunetta E, Canti V, Cardinaletti P, Ceccarelli F, Ciccia F, Conti F, De Marchi G, de Paulis A, De Vita S, Emmi G, Faggioli P, Fasano S, Fredi M, Gabrielli A, Gasparotto M, Gerli R, Gerosa M, Govoni M, Gremese E, Laria A, Larosa M, Mosca M, Orsolini G, Pazzola G, Petricca L, Ramirez GA, Regola F, Rossi FW, Rossini M, Salvarani C, Scarpato S, Tani C, Tincani A, Ubiali T, Urban ML, Zen M, Doria A, Iaccarino L.
    J Autoimmun; 2021 Nov 17; 124():102729. PubMed ID: 34600347
    [Abstract] [Full Text] [Related]

  • 8. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K, Kurita N, Noma H, Matsuki T, Quasny H, Levy RA, Jones-Leone AR, Gairy K, Yajima N.
    Lupus Sci Med; 2022 Sep 17; 9(1):. PubMed ID: 37017254
    [Abstract] [Full Text] [Related]

  • 9. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
    Wallace DJ, Atsumi T, Daniels M, Hammer A, Meizlik P, Quasny H, Schwarting A, Zhang F, Roth DA.
    Lupus; 2022 Nov 17; 31(13):1649-1659. PubMed ID: 36206400
    [Abstract] [Full Text] [Related]

  • 10. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 17; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 11. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
    van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):281-291. PubMed ID: 31302695
    [Abstract] [Full Text] [Related]

  • 13. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
    Anders HJ, Furie R, Malvar A, Zhao MH, Hiromura K, Weinmann-Menke J, Green Y, Jones-Leone A, Negrini D, Levy RA, Lightstone L, Tanaka Y, Rovin BH.
    Nephrol Dial Transplant; 2023 Nov 30; 38(12):2733-2742. PubMed ID: 37463054
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 30; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 15. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec 30; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T, Neuner R, Thompson A, Pottackal G, Petullo D, Liu J, Nikolov N, Sahajwalla C, Doddapaneni S, Chen J.
    Lupus; 2022 Apr 30; 31(4):424-432. PubMed ID: 35238725
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H, Chen J, Zhang Y, Zhao N, Xu D.
    Ren Fail; 2023 Dec 30; 45(1):2207671. PubMed ID: 37194710
    [Abstract] [Full Text] [Related]

  • 18. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 30; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB.
    Lancet; 2021 May 29; 397(10289):2070-2080. PubMed ID: 33971155
    [Abstract] [Full Text] [Related]

  • 20. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S, Ehreiser L, Anders J, Anders HJ.
    Front Immunol; 2022 May 29; 13():999704. PubMed ID: 36211360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.